Quick Answer
Connect Biopharma Holdings Ltd reported Research And Development Expense of $37.80 million for the year ending 2025.
- Connect Biopharma Holdings Ltd showed an increase of +29.2% in Research And Development Expense from 2024 to 2025.
- This data is from Connect Biopharma Holdings Ltd's annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2024: $8.66 million | Q2 2024: $5.35 million | Q3 2024: $9.01 million | Q1 2025: $6.63 million | Q2 2025: $8.77 million | Q3 2025: $11.11 million.
- Over the full 7 years of available data (2019 to 2025), Connect Biopharma Holdings Ltd's Research And Development Expense has declined by 64.5%.
- Historical annual values: Fiscal year 2025: $37.80 million | Fiscal year 2024: $29.26 million | Fiscal year 2023: $53.00 million | Fiscal year 2022: $96.63 million | Fiscal year 2021: $80.50 million | Fiscal year 2020: $150.93 million | Fiscal year 2019: $106.41 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: